Drug Profile
RT 001
Alternative Names: Di-deuterated ethyl linoleate; Di-deuterated linoleic acid ethyl ester; RT-001 - Retrotope; RT001Latest Information Update: 15 Nov 2023
Price :
$50
*
At a glance
- Originator Retrotope
- Developer BioJiva; Retrotope
- Class Antidementias; Antiparkinsonians; Antivirals; Neuroprotectants; Unsaturated fatty acids
- Mechanism of Action Lipid peroxidation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Neuroaxonal dystrophies
- Phase II Amyotrophic lateral sclerosis; Progressive supranuclear palsy
- Discontinued Alzheimer's disease; COVID 2019 infections; Friedreich's ataxia; Huntington's disease; Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 15 Sep 2022 Retrotope completes a phase II trial in Amyotrophic lateral sclerosis in Estonia, Latvia, the Netherlands and Sweden (PO) (NCT04762589)
- 15 Sep 2022 Efficacy data from a phase II trial in amyotrophic lateral sclerosis released by BioJiva
- 28 Aug 2022 No recent reports of development identified for preclinical development in Huntington's-disease in USA (PO)